Latest Information
June 16th, 2017
Add greater risk of kidney and bladder cancer to the long list of why a lifetime of sitting on the sofa isn't good for your health, a new study suggests.

June 8th, 2017
Pazopanib 600 mg daily as adjuvant therapy did not prolong disease-free survival for patients with locally advanced renal cell carcinoma (RCC) who had undergone nephrectomy, according to the results of the phase III PROTECT trial (abstract 4507).
June 1st, 2017
The FDA has granted a priority review designation to sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who have received nephrectomy and are high risk for recurrence
Print this page Tell A Friend Add to Favorites

Dr. Kevin Zbuk

B.Sc. (Alberta), MD (Alberta), FRCPC


Assistant Professor, McMaster University
Department of Oncology - Division of Medical Oncology




Office:

Juravinski Cancer Centre
3rd Floor
699 Concession Street
Hamilton Ontario, L8V 5C2

Contact Information:
P: 905-387-9711 Ext. 64602
F: 905-575-6326
E:kevin.zbuk@jcc.hhsc.ca

Support Staff:
Karen Chadwick (Administrative Assistant)
P: 905-387-9711 Ext. 64602
F: 905-575-6326
E: Karen.Chadwick@jcc.hhsc.ca

Areas of Interest

Dr. Zbuk's areas of interest include cancer genetics and the molecular classification of gastrointestinal polyposis syndromes. Dr. Zbuk's oncology practice focuses on gastrointestinal malignancies.

Selected Publications

Zbuk K and Eng C “Cancer Phenomics: RET and PTEN as illustrative models”. Nature Reviews Cancer. 2007 Jan;7(1):35-45.

Ni Y*, Zbuk K*, Sadler T, et. al. « Germline mutations and variants in the succinate dehydrogenase genes in Cowden andCowden-like syndromes” American Journal of Human Genetics 2008 (in press)

Plon, S.E., Pirics, M.L., Agrawal, S., Zbuk, K., Nuchtern, J., Hicks, J., Hegde, M., Lip-Hon Chin, E., Eng, C., and H. Russell (2008). Multiple Tumors in a Child with Germline Mutations in TP53 and PTEN. New England J of Medicine, in press.

* joint first authors